Navigation Links
Major grant advances UW's clinical and translational research enterprise
Date:9/18/2007

MADISON -- The National Institutes of Health (NIH) has awarded the University of Wisconsin-Madison's new Institute for Clinical and Translational Research (ICTR) one of the largest grants in the history of the UW School of Medicine and Public Health, making UW-Madison a key player in an ambitious NIH plan to transform the country's clinical and translational research enterprise.

The primary goal of the plan is to find ways to do a better job of moving biomedical and health sciences discoveries into practical use in health care providers' offices, clinics and hospitals, where the new knowledge can be used most rapidly and effectively to improve peoples' health.

With $41 million over five years, ICTR will aggressively address clinical and translational research in Wisconsin by first building a network of key partners from across campus and around the state. Representatives of the four UW-Madison health sciences schools (medicine and public health, nursing, pharmacy and veterinary medicine) and the College of Engineering are integrally involved, along with the Marshfield Clinic.

With an infrastructure in place, the institute will expand training programs and coordinate an array of resources and services for both new and established investigators. Input from public health departments and community health offices throughout Wisconsin will be essential to ensuring that the research is relevant and reaches people and areas with the greatest needs.

"When you combine UW-Madison's world-class strengths in both the basic and clinical sciences, its developing strength in public health and the collaborations it has nurtured with health care and public health institutions around the state, it makes complete sense that the university would be chosen to be involved in this transformative national initiative," says UW-Madison Chancellor John D. Wiley. "The opening of our Wisconsin Institute of Discovery and Interdisciplinary Research Com
'/>"/>

Contact: Dian Land
dj.land@hosp.wisc.edu
608-261-1034
University of Wisconsin-Madison
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Pharma majors gear to supply anti-anthrax drug
2. First Artificial Heart patient has Major setback
3. Allergies: A major health problem
4. Animal insulin product to be discontinued by drug major Eli Lilly
5. Vision Loss Due To Diabetic Retinopathy a Major Cause Of Concern
6. Depression Found To Be A Major Cause for Death in Elderly
7. Genetics Has A Major Role To Play In Body Shape.
8. “Yes, I need Cosmetic surgery” – view of majority wome
9. Pigs Population A Major Threat To Encephalitis Ravaged UP
10. Unsafe Injections and Unclean Hand hygiene major cause of hospital infections in India
11. Delhi Government To Interlink All Major Hospitals Through e-Governance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...may reduce future disease burden, researchers say ...Encouraging city dwellers to walk and bicycle inst...health benefits than increased used of low-emissio...study compared the projected health effects in 203...r London, England, and Delhi, India: business-as-...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...te (TM) has been shown in studies to be effective ...ed by an overload of copper, and certain metastati...r, is known about how the drug works at the molecu...versity researchers now has provided an invaluable... to copper-loaded metallochaperones. The drug sequ...
(Date:11/26/2009)...tal (RTDental), a leading dental group practice in...sion of its services to include LUMINEERS by a cer... Durham, NC (PRWEB) -- Res...Dr. Doug Macmillan, an experienced LUMINEERS Den...aining seminar. RTDental’s ability to fulfi...
(Date:11/25/2009)...wswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. ...will host two investor events in December: ,, ....m. CT/10:00 a.m. ET ,, Principal investigato...filzomib in relapsed and/or refractory multiple my... Hematology (ASH) Annual Meeting and Exposition in...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...sis by the Health Department and the consequent qu...y in New York heavily. It has to cough up $75,000... officials ordered Maureen Ryan, 64, a nursing cas...ounty Attorney Lori Alesio and Ryan's lawyer, Kevi...
...ildren's Research Hospital have discovered inherit...with acute lymphoblastic leukemia (ALL) susceptib...y medications. The researchers showed that these v...o have its intended effect). The findings,...
...or patching holes in the heart may make it possibl...d others to regain enough strength to safely unde...a study reported at the 30th Annual Scientific Ses...r septal defects(VSDs)or ruptures in the wall betw...
...e Minister, Dr. Anbumani Ramados, speaking at the ...today , said that under the National Rural Health ... 200,000 nursing personnel to provide comprehensiv...tional nursing training institutions. Welcoming th...
...Spears' come-back album will supposedly not talk a...st few months but will instead "celebrate womanhoo... the songs, said the album is not going to be abou...ther way. She didn't let any of her personal life ...
...rs when he taunted supermodel Kate Moss and asked ...h. Moss reportedly walked past the boy in a New ...eports mirror.co.uk. The schoolboy, who had been w...mous women being heckled by a fresh-faced schoolbo...
Other Medicine News:Health News:US County to Compensate Woman Wrongly Quarantined for TB 2Health News:Inherited Genes Linked to Toxicity of Leukemia Therapy 2Health News:Novel Catheter Technique Successfully Patches Holes in the Heart 2Health News:Novel Catheter Technique Successfully Patches Holes in the Heart 3
(Date:11/25/2009)... The FDA granted traditional approv...-nucleoside reverse transcriptase inhibitor (NNRTI...ted for use in treatment-experienced adults who ar...s resistant to an NNRTI and other antiretroviral (... 48-week data from two Phase 3 studies known as DU...
(Date:11/25/2009)... 25 Regado Biosciences, a privatel...mbotic aptamers with active control agents, announ... be presenting at the Piper Jaffray 21st Annual He...in New York City. Dr. Mazzo,s presentation will b... will include an overview of the Company,s pipelin...
(Date:11/25/2009)... Abaxis, Inc. (Nasdaq: ...oint-of-care blood analysis systems, announced tod...ve officer, will present at the 21st Annual Piper ...ber 2, 2009 at 2:00 p.m. ET. The conference will b...ty. ,, About Abaxis ,, Abaxis develops, m...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2New synthetic molecules trigger immune response to HIV and prostate cancer 10644 1New synthetic molecules trigger immune response to HIV and prostate cancer 10644 2Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 1Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 2Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 3Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 4Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 5Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 6Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 60787 7Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 14742 1Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 14742 2
...g, SOMERSET, N.J., April 14 Alfacell Corporation...ee with the University of,Pennsylvania has reporte...,promising radiation sensitizer for lung cancer tr...o and in vitro data in a poster at the 2008 Americ...eting being held April 12 -,16 in San Diego., In ...
...il 14, at 8:30 a.m. E.T. at ...ril 14 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ...ase 2 open-label extension (OLE) study of mipomers...(FH). In FH patients exposed to,mipomersen for as ...continues to be encouraging. Reductions in LDL-cho...
Other Medicine Technology:Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 2Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6
...grade Holter Monitoring System, equipped with the ... ST analysis algorithm, Heart Rate Variability ana...cilities with an Epicardia System in place have co...hem to suit their needs, and managing their data. ...
...Zeiss Meditec product, designed to make the correc...iendly and individual. All the parameters of this ...reasing efficiency, achieving optimum treatment re...s here are the extremely fast ablation, customized...
R Series Code-Ready Defibrillator
TandemHeart Escort Controller
Medicine Products: